Skip to main content
ORNL researchers produced self-healable and highly adhesive elastomers, proving they self-repair in ambient conditions and underwater. This project garnered a 2021 R&D 100 Award. Credit: ORNL, U.S. Dept. of Energy

Research teams from the Department of Energy’s Oak Ridge National Laboratory and their technologies have received seven 2021 R&D 100 Awards, plus special recognition for a COVID-19-related project.

A traffic-camera view of Shallowford Road, one of the more than 350 intersections in Chattanooga studied by Oak Ridge National Laboratory researchers.

The daily traffic congestion along the streets and interstate lanes of Chattanooga could be headed the way of the horse and buggy with help from ORNL researchers.

Summer Widner, Stephanie Timbs, James Gaugler and James Avenell of ORNL are part of a team that processes thorium-228, a byproduct of actinium-227. As new uses for thorium are realized, particularly in medicine, the lab expects the demand for the radioisotope to grow.

As a medical isotope, thorium-228 has a lot of potential — and Oak Ridge National Laboratory produces a lot.

Researchers studying secondary metabolites in the fungus Aspergillus flavus, pictured, found unique mixes of metabolites corresponding to genetically distinct populations. The finding suggests local environmental conditions play a key role in secondary metabolite production, influencing the discovery of drugs and other useful compounds. Credit: Tomás Allen Rush/ORNL, U.S. Dept. of Energy.

Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus. Credit: Michelle Lehman/ORNL, U.S. Dept. of Energy

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.

L-R: ORNL’s Omer Onar and Veda Galigekere with the dynamic wireless charging test bed at ORNL’s Grid Research Integration and Deployment Center. Credit: Carlos Jones, ORNL/U.S. Dept. of Energy

Consumer buy-in is key to the future of a decarbonized transportation sector in which electric vehicles largely replace today’s conventionally fueled cars and trucks.

Belinda Akpa applies her diverse expertise and high-performance computing to accelerate the drug discovery process and increase the chances of success when candidate molecules go to clinical trials. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.

Heavy-duty vehicles contribute 23% of transportation emissions of greenhouse gases and account for almost one-quarter of the fuel consumed annually in the U.S. Credit: Chris Bair/Unsplash

Through a consortium of Department of Energy national laboratories, ORNL scientists are applying their expertise to provide solutions that enable the commercialization of emission-free hydrogen fuel cell technology for heavy-duty

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

ATOM logo

The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.